DRREDDY · NSE
Dr. Reddy's Laboratories
Phase 4 · Capital Return
Profitable, cash-generative, and returning capital to shareholders through dividends.
Phase 1
Startup
Phase 2
Hyper Growth
Phase 3
Operating Leverage
Phase 4
Capital Return
Phase 5
Decline
Revenue growth (YoY)
3.2%
Mar 2026 vs Mar 2025
Net profit growth (YoY)
-27.4%
Operating cash flow
₹5674 Cr
Mar 2026
Returning capital?
Yes
Last dividend ex-date 2026-07-09
Revenue, profit & operating cash flow
₹ crore, by fiscal year
RevenueNet profitOperating cash flowRevenue ends at ₹33700 Cr. Net profit ends at ₹4158 Cr. Operating cash flow ends at ₹5674 Cr.
Judge management on
Capital allocation — are dividends sized sensibly against free cash flow?
Key metric to watch
Free cash flow and the dividend payout ratio.
Typically valued on
Price/earnings and dividend yield.
| Fiscal year | Revenue | Net profit | Operating cash flow |
|---|---|---|---|
| Mar 2021 | ₹19048 Cr | ₹1952 Cr | ₹3570 Cr |
| Mar 2022 | ₹21545 Cr | ₹2182 Cr | ₹2811 Cr |
| Mar 2023 | ₹24670 Cr | ₹4507 Cr | ₹5888 Cr |
| Mar 2024 | ₹28011 Cr | ₹5578 Cr | ₹4543 Cr |
| Mar 2025 | ₹32644 Cr | ₹5725 Cr | ₹4643 Cr |
| Mar 2026 | ₹33700 Cr | ₹4158 Cr | ₹5674 Cr |
Advertisement